Literature DB >> 8123039

Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts.

V Midy1, J Plouët.   

Abstract

Vasculotropin/vascular endothelial growth factor (VAS/VEGF) is an angiogenic growth factor whose biological activity seems to be restricted in vitro to vascular endothelial cells. We describe here that fetal bovine osteoblasts (OB) bind VAS/VEGF but do not proliferate upon its addition. However VAS/VEGF induces migration, PTH-dependent cAMP accumulation and alkaline phosphatase increase when added to OB. The maximal effects reach levels comparable to that obtained with bone morphogenetic protein 2 (BMP-2), although the VAS/VEGF concentrations required are at least 100 fold lower. Our results suggest that VAS/VEGF could be an important regulator of osteoblastic differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8123039     DOI: 10.1006/bbrc.1994.1240

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  48 in total

Review 1.  Osteoblast migration in vertebrate bone.

Authors:  Antonia Thiel; Marie K Reumann; Adele Boskey; Johannes Wischmann; Rüdiger von Eisenhart-Rothe; Philipp Mayer-Kuckuk
Journal:  Biol Rev Camb Philos Soc       Date:  2017-06-19

Review 2.  Targeting polymer therapeutics to bone.

Authors:  Stewart A Low; Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-01-28       Impact factor: 15.470

3.  The dose of growth factors influences the synergistic effect of vascular endothelial growth factor on bone morphogenetic protein 4-induced ectopic bone formation.

Authors:  Guangheng Li; Karin Corsi-Payne; Bo Zheng; Arvydas Usas; Hairong Peng; Johnny Huard
Journal:  Tissue Eng Part A       Date:  2009-08       Impact factor: 3.845

4.  Angiogenic response to bioactive glass promotes bone healing in an irradiated calvarial defect.

Authors:  Ann Leu; Susanne M Stieger; Paul Dayton; Katherine W Ferrara; J Kent Leach
Journal:  Tissue Eng Part A       Date:  2009-04       Impact factor: 3.845

Review 5.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

6.  Hyaluronic acid hydrogels with controlled degradation properties for oriented bone regeneration.

Authors:  Jennifer Patterson; Ruth Siew; Susan W Herring; Angela S P Lin; Robert Guldberg; Patrick S Stayton
Journal:  Biomaterials       Date:  2010-06-23       Impact factor: 12.479

Review 7.  Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.

Authors:  John L Hamilton; Masashi Nagao; Brett R Levine; Di Chen; Bjorn R Olsen; Hee-Jeong Im
Journal:  J Bone Miner Res       Date:  2016-04-08       Impact factor: 6.741

8.  Dimethyloxaloylglycine increases the bone healing capacity of adipose-derived stem cells by promoting osteogenic differentiation and angiogenic potential.

Authors:  Hao Ding; You-Shui Gao; Yang Wang; Chen Hu; Yuan Sun; Changqing Zhang
Journal:  Stem Cells Dev       Date:  2014-01-24       Impact factor: 3.272

9.  Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model.

Authors:  Zarana S Patel; Simon Young; Yasuhiko Tabata; John A Jansen; Mark E K Wong; Antonios G Mikos
Journal:  Bone       Date:  2008-07-14       Impact factor: 4.398

10.  Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation.

Authors:  Yanqiu Liu; Agnes D Berendsen; Shidong Jia; Sutada Lotinun; Roland Baron; Napoleone Ferrara; Bjorn R Olsen
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.